



Quarterly Business Update

October 2021

Notice: Forward looking statements

The purpose of the presentation is to provide an update of the business of Genetic Technologies Limited (the Company) ACN: 009 212 328 (ASX:GTG; NASDAQ:GENE). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by the Company and should not be relied upon as an independent source of information. Please refer to the Company's website and/or the Company's filings to the ASX and SEC for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by the Company. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

Unlocking personalised preventative health

Significant progress has been made in understanding the role of hereditary risk in chronic disease, however, many chronic conditions cannot be predicted by this risk alone.

We're transforming the conversation. Transitioning from a one-size-fits-all model to personalised, predictive health assessment – where each person has the information, they need to manage their health according to their own risk.

Backed by over 20 years of experience, our doctors, scientist and technicians are translating genetic information into multi-tests that uniquely combine genetic and clinical risk models to predict risk of chronic diseases before onset.

We're empowering physicians to improve health outcomes for people around the world. Tracking disease to its source. Enabling a new era of personalised medicine.



Our Overview

01

Our Vision & Brand Pillars

2021 Overview
Where are we now

02

Our Markets

Prioritising the market entry strategy by region

03

Our Acquisition

EasyDNA - Building our Direct-to-Consumer growth pathway

04

Our Channels & Divisions

Focused on three distinct and target routes to market

05

Our Portfolio & Innovation


Executing through cutting edge innovation and 'game changing' partnerships

06

Our Capabilities

Aligning our internal capability aligned to execution

Highlights and Results overview – Qtr. 1, 2021



- Cash receipts of A\$850k, a material increase on the prior quarter
- Acquired, settled and integrated the acquisition of EasyDNA, the primary channel for the increase in cash from operations, for US\$4 million in cash and scrip
- Completed and submitted NATA validation pack for the Multi-Test; final step prior to the commercial launch of the Multi-Test
- Invested in self-funded collaborative study to enable expanded Breast Cancer risk testing for populations of African descent with Professor Colditz at Washington State University
- Published peer-reviewed paper titled “Ability of known colorectal cancer susceptibility SNPs to predict colorectal cancer risk: A cohort study within the UK Biobank” Gafni A, Dite GS, Spaeth Tuff E, Allman R, Hopper JL (2021) on PLoS
- Strong cash balance of A\$15.7 million, providing 24 months of runway post the integration and revenue contribution from EasyDNA
- Net cash used for operations of A\$1.9 million, due mainly to the increase in R&D and operating expenses as the Company executes on its commercialisation strategy

01: Our 2021 Snapshot



Signed multi-year distribution agreement

License and distribution agreement for COVID-19 Risk Test with IBX
Launched CIT in USA & AUS for other tests¹



Focused on commercialisation of R&D

Over a decade of R&D translating to commercial launch of geneType for Breast Cancer, Colorectal Cancer & COVID-19 African American Breast Cancer Research Collaboration with Professor Colditz at Washington State University



On track to launch new Multi-test

New Multi-test development on track for serious disease risk including major oncological, metabolic and degenerative diseases - covering up to 70% of mortalities and morbidities



Acquired revenue generating platform

Acquired EasyDNA for US\$4m in cash and script² providing global platform with US\$4.63m in unaudited revenue in CY20



Solid balance sheet

A\$15.7million cash balance following settlement of EasyDNA, providing a 24-month runway



Robust patent portfolio & clinical credibility

17 patents granted and 9 patent families pending multiple peer-reviewed publications and four collaborations with prestigious academic and medical establishments

1. geneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.
2. Runway based on current cash projections and including the acquisition of EasyDNA

02: Our Markets and Collaborators

United States

geneType® Polygenic Risk Score (PRS) tests for breast, colorectal cancer and COVID-19 Risk Test available through **CLIA** Certified “High Complexity” Laboratories.

Further products expected to be submitted in next 12 months

Europe & UK

Commencing CE certification enabling EU launch of Novel genetic risk test in CY2021

EasyDNA available multiple EU countries and UK

Asia

(Inc. SEA, China and India)

H2 CY2021 to commence a scoping and Prioritising a market entry strategy into Asia

EasyDNA available in multiple countries across SEA

Australia & New Zealand

Certification by Australian regulators **NATA**, to sell into the Australian market

Two products¹ currently certified and further products expected to be submitted in next 12 months



Memorial Sloan Kettering
Cancer Center.



THE UNIVERSITY OF
MELBOURNE



Washington University in St. Louis
INSTITUTE FOR PUBLIC HEALTH



UNIVERSITY OF
CAMBRIDGE



¹ GeneType for Breast Cancer and Colorectal Cancer certified for sale via online sales platform.

02: A strategy to own the personalised, preventative health testing market

Brand Recognition and Advocacy



Thought leadership

Demonstrating our leadership by informing the conversation on personalised, preventative health care



Seeded content

Amplifying our impact by starting and informing conversations in key consumer and clinical channels



geneType advocacy

Building a group of clinicians and consumers willing to share with their colleagues and friends their experience with geneType

Commercialization and Branding



Sales & marketing

Core set of sales and marketing tactics and assets tailored by therapeutic area, and adapted by geography



Medical education


Motivating trial and purchase with medical education for clinicians and consumers




geneType Hubs

Empowering clinicians to use geneType. Their clinic becomes a geneType Hub that taps into a GP referral network and reinforcing their leadership in personalised, preventative health care


02: A cutting-edge geneType brand set for relaunch



Mobile




Digital



Education

02: Core set of sales material to empower clinicians and consumers to trial and use geneType tests



03: EasyDNA – Acquisition of DTC Platform


- Acquired EasyDNA in August 2021 for US\$4 million
- Current revenues of US\$4.63 million through retail sales of its at-home DNA tests
- Agreements with 12 laboratories in North America, AsiaPac and Europe
- A platform to launch the geneType Multi Test and portfolio of serious disease tests across 40 countries*



easyDNA®

03: EasyDNA – Establishing our Lifestyle Division

- Headed by Kevin Camilleri
- EasyDNA currently sells paternity, oncology and health and wellbeing genomics-based tests
- This acquisition provides Genetic Technologies the foundation to grow in **40 countries**
- Expand the health-related tests with an extensive DTC marketplace



04: Our Pathways

Medical – Business to Business (B2B)

A communication and execution plan curated for

Payers / Insurers

Primary Care Physicians

Specialists

Surgeons

Allied Health



Certifying reimbursable germline testing platform

BRCA test

LYNCH Syndrome test

*(More to follow)**



Consumer initiated testing (CIT) with medical supervision

Launched US and Australia CIT platforms in 2020 with medical supervision with:

InTeleLabs in the US

Phenix Health in Australia



Current products include:
geneType for Breast Cancer

geneType for Colorectal Cancer

AUD\$349 / US\$249 per test



Direct to consumer testing (DTC) with no medical supervision

Recent Acquisition announced for EasyDNA



Leverage for paternity, ancestry, gut microbiome testing and non-medical related genomic tests

www.Easydna.com



Provides Genetic Technologies the foundation to grow in **40 countries**


Agreements with **12 laboratories in North America, AsiaPac and Europe**



04: Our Divisions

 Emerging divisions

 Existing divisions



NEW – Universal collection test kit to support Multi Test Launch



NEW Universal sample collection kit with TGA, FDA and EU regulatory approval¹


BC = Breast Cancer; CRC = Colorectal Cancer; PC = Prostate Cancer; CVD = Cardiovascular Disease; IHD = Ischemic Heart Disease; Atrial Fibrillation

1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek


05: Our Innovation

geneType integrates genetic risk and clinical risk to better stratify individual risk. Patients with potentially high risk may exceed actionable clinical guidelines 10 – 15 years earlier than those with low risk ^{1,2,3}


Breast Cancer (BC)¹



Colorectal Cancer (CRC)²



Chronic Heart Disease (CHD)³



geneType detects patients at an actionable risk of serious disease
10 – 15 years earlier than currently possible
Potentially significantly improving patient outcomes and health economics

¹ Mavaddat et al. (2015) JNCI.

² Jenkins et al. (2019) Familial Cancer.

³ Abraham et al. (2016) Eur Heart J.

05: Our Portfolio – Driving Growth

CIT Platform in AUS and USA selling BRC and CRC




Moderate Revenue Expectations Q2 CY 2021

IBX COVID Risk Test released for sale May 31, 2021



Revenue Commenced Q2 CY 2021

100% Germline + PRS test for Breast Cancer and CRC to launch in AU & USA



Expanding into reimbursable space

Commercially Available Q4 CY 2021

Multi Test to provide risk assessment for >70% of all morbidities to launch



Market Release to include up to 70% of morbidity:

- Breast Cancer
- Colorectal Cancer
- Cardiovascular Disease
- Type 2 Diabetes
- Melanoma
- Prostate Cancer

Commercially Available Q4 CY 2021

December 2020

April 2021

July 2021

H2 2021



05: Significant market opportunity

To provide predictive, pre-symptomatic testing to inform lifestyle choices and healthcare discussions
Guideline driven, reimbursable for inherited and non inherited disease

Near Term Addressable Market

281,550⁵
 Diagnosis of breast cancer
 annually in United States
(19,974 cases diagnosed annually in Australia³)

+

**1st degree
relatives**

=

GTG Target Market for

BRCA Panel + Breast Cancer PRS

Testing

providing up to 100% genetic
risk cover screening



149,500⁶
 Diagnosis of colorectal cancer
 annually in United States
(15,494 cases diagnosed annually in Australia⁴)

+

**1st degree
relatives**

=

GTG Target Market for

LYNCH Syndrome Panel + Colorectal

Cancer PRS Testing

providing up to 100% genetic
risk cover screening



Global Predictive Genetic Testing Market anticipated to exceed \$28bn by 2026¹

1. Genetic Testing Market Size By Test Type (Predictive Testing, Carrier Testing, Prenatal and New-born Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomic Testing), By Application (Cancer, Genetic Disease, Cardiovascular Disease), Industry Analysis Report, Regional Outlook, Application Potential, Competitive Market Share & Forecast, 2020 – 2026; Published Date: Feb 2020; Authors: Sumant Ugalmugle, Rupali Swain
2. PRS = Polygenic Risk Score
3. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/breast-cancer/breast-cancer-australia-statistics>
4. <https://www.canceraustralia.gov.au/affected-cancer/cancer-types/bowel-cancer/bowel-cancer-colorectal-cancer-australia-statistics>
5. <https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html>
6. <https://www.cancer.net/cancer-types/colorectal-cancer/statistics>

05: Our Innovation - Multi Test

A companion diagnostic PRS to help identify risk of serious disease for up to 70% of Mortalities and Morbidities
Committed to continually invest in developing multi population testing solutions

 Phase 1 Launch ²

 Phase 2 Launch ³

Oncology

Breast Cancer
Colorectal Cancer
Prostate Cancer
Melanoma
Pancreatic Cancer
Ovarian Cancer

1

Cardiovascular

Atrial Fibrillation
Coronary Artery Disease

2

Metabolic

Type 2 Diabetes

3

Mental Health

Taliaz

4

GeneType Multi-test to include
>70% of mortality & morbidity



NEW Universal sample collection kit with
TGA, FDA and EU regulatory approval¹


1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
2. Commercial availability expected Q4 CY2021
3. Commercial availability expected Q1 CY2022

05: Our Innovation - Multi Test

Phase 1 Launch Test reports – NATA Validation pack submitted


Phase 1 Launch ²

Phase 2 Launch ³



1. TGA, FDA and EU regulatory approval granted to the sponsor, DNA Genotek
2. Commercial availability expected Q4 CY2021
3. Commercial availability expected Q1 CY2022

06: Our Capability





01

**Our Vision &
Brand Pillars**

02

Our Markets

Targeted and
deliberate

03

Our Acquisition

Positioned for
growth

04

**Our Channels &
Divisions**

Focused and
distinct

05

**Our Portfolio &
Innovation**

Cutting edge
innovation

06

Our Capabilities

Aligned to
execute





Thank you

Corporate
Simon Morriss
Genetic Technologies
simon.morriss@gtglabs.com

Investor Relations
Stephanie Ottens
+61 434 405 400
stephanie.ottens@marketeye.com.au



Appendices

Our Intellectual Property

7 Patents granted in the US

- Patent 11,031,098, Computer systems and methods for genomic analysis
- Patent 10,683,549, Methods for assessing risk of developing breast cancer
- Patent Nos. 9,051,617; 9,068,229 and 9,702,011 covering three of the core genetic markers included in the BREVAGenplus® risk assessment test
- Patent No. 7,127,355 offering broad protection re: methods of genetic analysis (the concept of combining clinical risk assessment with genetic risk factors to improve predictability over clinical risk assessment alone)
- Patent No. 6,969,589 covering the identification of informative SNPs

5 Patents granted in China

- Patent Nos. 200680051710.0; 201310524782.4; 201310524916.2 and 201310524765.0 “Markers for Breast Cancer”
- Patent No. 201080033130.5 Methods for Breast Cancer Risk Assessment

5 Patents granted in Hong Kong

- Patent Nos. 09101235.4; 12112875.1; 12112368.5 and 12112874.2 “Markers for Breast Cancer”
- Patent No. 12109000.5 Methods for Breast Cancer Risk Assessment

9 Patent families pending

- Methods for breast cancer risk assessment
- Methods for assessing risk of developing breast cancer
- Improved methods for assessing risk of developing breast cancer
- Markers for breast cancer
- Methods for genetic analysis
- Methods for genomic analysis
- Methods for assessing risk of developing colorectal cancer
- Methods of assessing risk developing a disease
- Methods for assessing risk of developing a severe response to coronavirus infection

Board and Management: Sales and Scientific expertise leading GTG



Mr. Peter Rubinstein

BEC, LLB
Chairman - Non – Executive
Director



Dr. Lindsay Wakefield

MBBS
Non – Executive Director



Mr Nick Burrows

B.Com, FAICD, FCA,
FGIA, FTIA, F Fin
Non – Executive Director



Simon Morriss

GAICD
Chief Executive Officer



Dr. Jerzy “George” Muchnicki

MBBS
Executive Director & Chief
Medical Officer



Erika Spaeth

PhD
Director of Clinical Affairs &
Medical Education



Richard Allman

BSc, PhD
Chief Scientific Officer



Mike Tonroe

BSc, FCA, MAICD
Chief Financial Officer



Carl Stubbings

Chief Commercial Officer

Strong Scientific Leadership: Advisory Board



Professor Jon Emery

MBBCh MA DPhil FRACGP MRCGP
Research & Education Lead, Primary Care
Integration, Victorian Comprehensive
Cancer Centre Herman Chair of Primary
Care Cancer Research, University of
Melbourne



Professor Finlay Macrae AO

MBBS, MD, FRACP, FRCP, AGAF MWGO is
Principal Fellow and Professor, Department
of Medicine, University of Melbourne, and
Head of Colorectal Medicine and Genetics,
The Royal Melbourne Hospital



Ora K. Gordon, M.D.

MD, MS, FACMG
Regional Medical Director, Center for
Clinical Genetics & Genomics. Clinical
Director, PSJH Population Health Genomics
Program. Chair, Integrated Network Cancer
Program, Professor of Genetics, St John
Cancer Institute


Financial Overview

- Cash burn of A\$1.94 million a decrease on prior quarter (Q4 FY'21: A\$2.12 million) as a result of product sales, mainly from the EasyDNA brand
- Cash reserves of A\$15.7 million after EasyDNA acquisition costs of A\$3.5 million give 24 month runway to:
 - Support the introduction and distribution of new geneType products in the United States and Europe
 - Develop the direct-to-consumer sales channel through EasyDNA
 - Reimbursement studies for the polygenic risk tests;
 - Introduction of germline testing division;
 - General product research and development; and
 - For general working capital and potential acquisitions.

\$A'000	30 June 2021	30 Sep 2021	Change
Net operating cashflow	(2,116)	(1,939)	8%
Receipts from customers	850	68	92%
Research and Development and Staff costs	1,215	1,321	(9%)
Cash	20,903	15,742	(25%)

Corporate Overview

Top 50 share registry breakdown



Dual Listed on the ASX and Nasdaq

Financial Information

Share price (AUD) as at 18 October 2021 0.7c

ADR price (USD) as at 18 October 2021 \$3.00

Ord Shares on Issue (M) 9,226

ASX 52-week trading (AUD low/high) 0.6/1.4c

Nasdaq 52-week trading (USD low/high) 2.77/8.18

Market Cap (A\$/US\$M) 64.58/46.13

Cash at 30 June 2021 A\$20.9m

Cash at 30 September 2021 A\$15.7m

Debt (30 June and 30 September 2021) nil

Defined Terms

Common Complex Diseases (CCP) – A complex disease is caused by the interaction of multiple genes and environmental factors. Complex diseases are also called multifactorial. Examples of common complex diseases include cancer and heart disease.

Polygenic risk score - a number associated with one's disease risk based on the aggregated effects of individual risk variants through a multiplicative algorithm.

Variant - Single Nucleotide polymorphism (SNP), an alteration in DNA that may be a common or rare event.

Genomic - pertaining to function of genetics from structure to relationship between genetic events.

Genetic - pertaining to a gene.

GWAS - genome-wide association studies are large population level studies which enable scientists to identify genes and genetic markers involved in human disease. This method searches the genome for SNPs that occur more frequently in people with a particular disease than in people without the disease. Each study can look at hundreds or many thousands of SNPs at the same time. Researchers use data from this type of study to pinpoint genetic variations that may contribute to a person's risk of developing a certain disease.

SNP - Single nucleotide polymorphisms, frequently called SNPs (pronounced "snips"), are the most common type of genetic variation among people. Each SNP represents a difference in a single DNA building block, called a nucleotide. For example, a SNP may replace the nucleotide cytosine (C) with the nucleotide thymine (T) in a certain stretch of DNA.

Serious Disease Risk (SDR) - Risk associated with acquiring COVID-19 and requiring hospitalisation with its associated morbidities and mortalities.

Germline Testing – Germline testing is done on cells that do not have cancer. It is done to see if a person has a gene mutation that is known to increase the risk of developing cancers and other health problems. This test uses cells (such as blood or skin cells) that do not have any cancer cells. Germline mutations can sometimes be passed down from parents.

Clinical Laboratory Improvement Amendments (CLIA) - Regulates laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing

National Association of Testing Authorities (NATA) - the authority responsible for the accreditation of laboratories, inspection bodies, calibration services, producers of certified reference materials and proficiency testing scheme providers throughout Australia. It is also Australia's compliance monitoring authority for the OECD Principles of GLP. NATA provides independent assurance of technical competence through a proven network of best practice industry experts for customers who require confidence in the delivery of their products and services.

Next Generation Sequencing (NGS) – Next-generation sequencing (NGS), also known as high-throughput sequencing, is the catch-all term used to describe a number of different modern sequencing technologies. These technologies allow for sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing, and as such revolutionised the study of genomics and molecular biology.

Laboratory Developed Tests (LDT) – A type of in vitro diagnostic test that is designed, manufactured and used within a single laboratory.

Consumer Initiated Tests (CIT) - laboratory testing that is initiated by the consumer without a physician order but reviewed and communicated back to the consumer via a physician.

Direct to Consumer (DTC) – laboratory testing that is initiated by the consumer without a physician order. The results are reported back directly to the consumer.